EGFR and neoplasm: Tumor types where anti-PD-(L)1 is approved was very limited and showed a modest correlation (Rho > 0.4 and ≤0.5), including for EGFR: CHOL, LIHC, KIRC and BRCA-basal, and for MET: bladder cancer (BLCA) and LUAD (Figure 3A,B).